Filing Flows › Comparisons › CAI vs LMRI
Caris Life Sciences vs Lumexa Imaging Holdings: CAI and LMRI compared
Caris Life Sciences is the larger company: $275M of revenue in its latest quarter (Q3 2026) against $264M for Lumexa Imaging Holdings (Q2 2026). Caris Life Sciences is growing faster (+27% against +5% a year earlier). Lumexa Imaging Holdings is more profitable, with an operating margin of 8.7% against 7.0%.
Where the money goes: CAI and LMRI
Caris Life Sciences (CAI) · Q3 2026
Caris Life Sciences, Q3 2026: revenue $275M (+27% year over year), operating margin 7.0%, net earnings $15.2M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Lumexa Imaging Holdings (LMRI) · Q2 2026
Lumexa Imaging Holdings, Q2 2026: revenue $264M (+5% year over year), operating margin 8.7%, net earnings $2.7M, operating cash flow $32.8M. The chart follows the revenue to costs, profit and cash.
| Caris Life Sciences (CAI) | Lumexa Imaging Holdings (LMRI) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $275M | $264M |
| Revenue growth, Y/Y | +27% | +5% |
| Operating margin | 7.0% | 8.7% |
| Net earnings | $15.2M | $2.7M |
| Net margin | 5.5% | 1.0% |
| Operating cash flow | −$22.2M | $32.8M |
| Free cash flow | — | $23.1M |
Where the revenue comes from
Caris Life Sciences
- Molecular Profiling Services: $263M (95%)
- Pharma Research and Development Services: $12.7M (5%)
Lumexa Imaging Holdings
- Health Care Patient Service: $195M (74%)
- Management Fee and Other Revenue Related Party: $51.7M (20%)
- Patient Service Revenue Related Party: $8.8M (3%)
- Investment Advisory Management and Administrative Service: $8.7M (3%)
Questions
Which is bigger, Caris Life Sciences or Lumexa Imaging Holdings?
Caris Life Sciences is the larger company: $275M of revenue in its latest quarter (Q3 2026) against $264M for Lumexa Imaging Holdings (Q2 2026).
Is Caris Life Sciences or Lumexa Imaging Holdings growing faster?
Caris Life Sciences is growing faster (+27% against +5% a year earlier).
Which is more profitable, Caris Life Sciences or Lumexa Imaging Holdings?
Lumexa Imaging Holdings is more profitable, with an operating margin of 8.7% against 7.0%.
More: Caris Life Sciences earnings · how Caris Life Sciences makes money · Lumexa Imaging Holdings earnings · how Lumexa Imaging Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.